1
Clinical Trials associated with Epoetin Alfa Biosimilar (Megalabs)Phase III, Multicentre, Double-blind, Randomised, Parallel, Equivalence Clinical Trial to Assess Efficacy, Safety of Megalabs® Recombinant i/v Human Erythropoietin Compared to Epogen® in Anaemia in Patients With Chronic Kidney Disease
Phase III, multicentre, double-blind, randomised, parallel, equivalence clinical trial to determine the efficacy, safety and immunogenicity of Megalabs® recombinant human alfa epoetin for intravenous use, compared to Epogen®, in the treatment of anaemia in participants with chronic renal disease, dependent on haemodialysis
100 Clinical Results associated with Epoetin Alfa Biosimilar (Megalabs)
100 Translational Medicine associated with Epoetin Alfa Biosimilar (Megalabs)
100 Patents (Medical) associated with Epoetin Alfa Biosimilar (Megalabs)
100 Deals associated with Epoetin Alfa Biosimilar (Megalabs)